ClinicalTrials.gg
CompletedNCT06437639Updated Dec 12, 2025

MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

A Phase 4 interventional study of Mexidol in Primary Open-Angle Glaucoma (POAG), sponsored by Pharmasoft. Completed at 1 site in Russia. Open to participants aged 50 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Pharmasoft · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2023, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years to 65 Years
Sex
All
01

Study summary

Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.

Read the detailed description

Hypothesis: Mexidol® allows to optimize POAG therapy by reducing mitochondrial dysfunction and stabilizing glaucomatous optic neuropathy by improving the functional activity of mitochondria and its energy-producing function

02

Conditions studied

  • Primary Open-Angle Glaucoma (POAG)

Keywords

  • Glaucoma
  • Primary Open-Angle Glaucoma (POAG)
  • Glaucomatous Optic Neuropathy (GON)
  • Mitochondrial Dysfunction
  • Neuroprotection
  • Mexidol
  • Ethylmethylhydroxypyridine Succinate
03

In context

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 80 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Pharmasoft is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An advanced stage of POAG in one or two eyes
  • Hypotonic-compensated intraocular pressure (IOP)

Exclusion criteria

Exclusion Criteria:

  • Degenerative diseases of the central nervous system, diabetes mellitus
  • Primary mitochondrial dysfunction
  • A history of surgical interventions and damage to the organ of vision
  • Acute or chronic inflammatory or hereditary degenerative eye diseases (anterior and posterior sections)
  • Decompensation of concomitant somatic diseases
  • Taking antioxidants/nootropic drugs 6 months before inclusion in the study
  • to ethylmethylhydroxypyridine succinate or to any of the
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Main (Mexidol and standard therapy)

    Mexidol IM 300 mg for 14 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 8 weeks; IOP normalizing therapy

    Drug: Mexidol

  • No intervention
    Control (standard therapy)

    IOP normalizing therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Degree of expression of mitochondrial dysfunction

    Enzyme status of lymphocytes (Succinate dehydrogenase and Glycerophosphate dehydrogenase)

    Time frame: 90 days

  2. Dynamics of the structural and functional characteristics of mitochondria

    Cytomorphodensitometry (number of mitochondria, their optical density, number of granules and deposits in the mitochondria of lymphocytes)

    Time frame: 90 days

Secondary outcomes

  1. Аssessment of differential light sensitivity of the retina

    Dynamics of index of mean deviation (MD) of retinal photosensitivity \[Static Automated Perimetry (SAP)\]

    Time frame: 90 days

  2. Structural and topographic changes in the layer of nerve fibers and the retinal ganglion [Optical Coherence Tomography (OCT) parameters]

    The average thickness of retinal nerve fibers (RNFL) of the peripapillary zone in four quadrants was studied using the Fast RNFL Thickness program and the thickness of the retinal ganglion cell complex (GCC-Ganglion Cell Complex protocol)

    Time frame: 90 days

  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Adverse events related to Mexidol

    Time frame: 90 days

07

Study locations

1 site
  • Tyumen Scientific Center of the Russian Academy of Sciences
    Tyumen, Russian Federation 625026, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Nov 2023, 2 months.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
May 31, 2024
StartActual
Sep 15, 2023
Primary completionActual
Nov 29, 2023
CompletionActual
Feb 2, 2024
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06437639
Lead sponsor
Pharmasoft
Responsible party
Sponsor
First posted
May 31, 2024
Start date
Sep 15, 2023
Primary completion
Nov 29, 2023
Completion
Feb 2, 2024
Last update
Dec 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion